NEW YORK (360Dx) – BioMérieux announced today it has acquired a 54 percent stake in Chinese immunoassay firm Suzhou Hybiome Biomedical Engineering.

Hybiome is located in Suzhou and specializes in automated immunoassays. BioMérieux acquired a minority stake in the company in July. 

BioMérieux said "the acquisition of 54 percent of the shares of Hybiome relies on a €165 million [$187 million] valuation" and it is incurring an additional €25 million in expenses for assets such as distribution rights and the existing installed base.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.